RBV Capital
VC Fund
Moscow, Russian Federation
RBV Capital is a dedicated life sciences venture fund based in Moscow, Russia with partnership office in Wilen, Switzerland. We invest into diversified assets in pharmaceuticals, biologics, digital healthcare products and medical devices answering to an unmet medical and market need and with a potential for global outreach.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries RBV Capital invests in
Stages RBV Capital invests in
Countries RBV Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series B
- $1.7M–$20M
Investment Focus
Industry
- Biotechnology 5 (71%)
- Therapeutics 4 (57%)
- Health Care 3 (43%)
- Life Science 2 (29%)
- Pharmaceutical 2 (29%)
Stage
- Series B 4 (57%)
- Series A 1 (14%)
- Series C 1 (14%)
- Funding Round 1 (14%)
Country
- United States 4 (57%)
- United Kingdom 1 (14%)
- Russian Federation 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alexey Konov
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Arseniy Shabashvili
Associate
|
Associate | Total investments: 0 | Find email | |
Robert Karl
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Contineum Therapeutics
|
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to thenervous system. | $80M / Series C / Feb 11, 2021 | |
Botkin.AI
|
Botkin.AI is a software-based platform for medical image processing and analysis based on artificial intelligence. The Company provides AI for analyzing radiograms and diagnosing the risk of tumors. The solution is based on deep machine learning. Botkin.AI significantly expands the radiologists’ ability to diagnose tumors and speeds up theprocessing of an increased flow of the patient’s clinical data without losing the quality of medical conclusions.It was founded in 2015 and is based in Moscow, Russian. | $1.7M / Series B / Dec 23, 2020 | |
|
Botkin.AI
|
Botkin.AI is a software-based platform for medical image processing and analysis based on artificial intelligence. The Company provides AI for analyzing radiograms and diagnosing the risk of tumors. The solution is based on deep machine learning. Botkin.AI significantly expands the radiologists’ ability to diagnose tumors and speeds up theprocessing of an increased flow of the patient’s clinical data without losing the quality of medical conclusions.It was founded in 2015 and is based in Moscow, Russian. | $1.5M / Series A / May 28, 2019 | |
Immusoft
|
Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft.Thetechnology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years.It was founded in 2009 and is headquartered in Seattle, Washington. | $20M / Series B / Jan 03, 2019 | |
Bonti
|
Endurance Biotech is a biotechnology company based in Orange, California. The company was founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad. | $11.7M / Series B / Apr 19, 2017 | |
RetroSense Therapeutics
|
RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients withthese retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital.Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan. | $6M / Series B / Nov 12, 2015 | |
IAG, Image Analysis Group
|
IAG, imaging expert company helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. This includes bringing AI, Machine Learning and smart image analysis methods to ensure the speed and cost-effectiveness, while delivering true insights about your mechanism of action and patients’ response, inreal-time. | $5.2M / Apr 30, 2015 |
Co-Investors
Orbita Capital Partners
2 deals together
Versant Ventures
2 deals together
Alexandria Venture Investments
1 deal together
Bios Partners
1 deal together
Blue Water Angels
1 deal together
Brace Pharma
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does RBV Capital invest in?
RBV Capital invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series A stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is RBV Capital's check size?
RBV Capital typically joins rounds of $1.7M–$20M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RBV Capital participates in.
How do I contact RBV Capital?
Public channels for RBV Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RBV Capital?
The team at RBV Capital includes Alexey Konov (Managing Partner), Arseniy Shabashvili (Associate) and Robert Karl (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
